Despite being a single-center, single-arm retrospective clinical study, our findings suggest that a combination therapy of TILs and anti-PD1 may be effective against metastatic cervical cancers resistant to chemotherapy, and in patients with low MSI expression and PDL1-negative. The gene discussed is CD274; the disease is cervical carcinoma.